Physician

Charles Clifton Wykoff, MD, PHD

According to 2025 Medicare claims, Charles Wykoff, MD, PHD (NPI: 1124237300) practices ophthalmology in the Houston-Pasadena-The Woodlands, TX market, with the plurality of this provider's patient population coming from Harris, TX. This provider's primary affiliated billing organization is RETINA CONSULTANTS OF HOUSTON PLLC (NPI: 1619135647; TIN: 74-2109903) and primary practice location at 77494-3286.

Wykoff's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,160 traditional Medicare patients, billed 42,254 HCPCS/CPT codes, and received $5,994,146 in Medicare payments. The top billing code was J0178 (Injection, aflibercept, 1 mg). Part D data shows 559 prescription claims across 185 beneficiaries totaling $37,168 in drug costs, led by Prednisolone Acetate (Prednisolone Acetate). Open Payments data shows 710 records totaling $16,578,117. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $3,004,522 to $5,994,146. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $26,457 to $37,168. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$3.1M$6.3M2015 Medicare payment: $3,004,522 (USD; Tot_Mdcr_Pymt_Amt)2016 Medicare payment: $3,250,271 (USD; Tot_Mdcr_Pymt_Amt)2017 Medicare payment: $3,841,628 (USD; Tot_Mdcr_Pymt_Amt)2018 Medicare payment: $3,817,193 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $4,548,772 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $5,147,997 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $5,186,090 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $5,166,737 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $6,279,407 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $5,994,146 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
201596113,167$3,004,522
20161,00114,990$3,250,271
20171,04416,849$3,841,628
20181,06016,722$3,817,193
20191,17119,374$4,548,772
20201,10421,057$5,147,997
20211,19021,384$5,186,090
20221,25322,217$5,166,737
20231,19833,161$6,279,407
20241,16042,254$5,994,146

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$39K$78K2015 Drug cost: $26,457 (USD; Tot_Drug_Cst)2016 Drug cost: $20,101 (USD; Tot_Drug_Cst)2017 Drug cost: $30,675 (USD; Tot_Drug_Cst)2018 Drug cost: $26,631 (USD; Tot_Drug_Cst)2019 Drug cost: $40,448 (USD; Tot_Drug_Cst)2020 Drug cost: $64,248 (USD; Tot_Drug_Cst)2021 Drug cost: $78,137 (USD; Tot_Drug_Cst)2022 Drug cost: $60,257 (USD; Tot_Drug_Cst)2023 Drug cost: $40,368 (USD; Tot_Drug_Cst)2024 Drug cost: $37,168 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
201599332$26,457
2016127373$20,101
2017149487$30,675
2018155411$26,631
2019199559$40,448
2020212591$64,248
2021198625$78,137
2022212638$60,257
2023204595$40,368
2024185559$37,168

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
J0178Injection, aflibercept, 1 mg3334,082$654
J2781Injection, pegcetacoplan, intravitreal, 1 mg12614,775$117
67028Injection of drug into eye4972,298$106
92014Established patient complete exam of visual system9401,801$92
92134Imaging of retina1,0683,086$31

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
Prednisolone AcetatePrednisolone Acetate1014,727$5,419
DifluprednateDifluprednate23563$3,612
Ketorolac TromethamineKetorolac Tromethamine1035,192$1,671
Atropine SulfateAtropine Sulfate281,668$1,369
Brimonidine TartrateBrimonidine Tartrate20854$922

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.122$394,856EyePoint Pharmaceuticals US, Inc.
Research PaymentsReported research-related payment or transfer-of-value amount.588$16,183,261Novartis Pharmaceuticals Corporation
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Charles Clifton Wykoff, MD, PHD?

Tedicare shows public-source Medicare data for Charles Clifton Wykoff, MD, PHD (NPI 1124237300), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Charles Clifton Wykoff, MD, PHD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Charles Clifton Wykoff, MD, PHD?

Charles Clifton Wykoff, MD, PHD is linked to RETINA CONSULTANTS OF HOUSTON PLLC (billing NPI 1619135647) in the available physician profile data.

Does Charles Clifton Wykoff, MD, PHD have Open Payments data?

Charles Clifton Wykoff, MD, PHD has 710 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.